Johnson & Johnson : What You Need to Know About Johnson & Johnson's 2021 Second-Quarter Earnings
July 21, 2021 at 08:41 am EDT
Share
Check out this infographic breakdown of the company's second-quarter 2021 performance, with key highlights from its Pharmaceutical, Consumer Health and Medical Device businesses.
By Johnson & JohnsonJuly 21, 2021
Today's Top Reads Close
alt
"How Johnson & Johnson Helped Us Adopt 11 Children"
Did you like reading this story? Click the heart to show your love.
209
How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
Did you like reading this story? Click the heart to show your love.
65
alt
5 Ways Johnson & Johnson Is Working to Improve the Well-Being of the World by 2025
Did you like reading this story? Click on the heart to show your love.
64
Share
Did you like reading this story? Click the heart to show your love.
1
expand
This morning, Johnson & Johnson shared its second-quarter performance.
Since its founding in 1886, the company has grown to become one of the world's largest and most broadly based healthcare companies, with approximately 136,000 employees across the globe working every day to help change the trajectory of health for humanity.
"Johnson & Johnson's second-quarter results were driven by strong performance across our three business units, exceeding expectations," says Joe WolkJoe Wolk,Executive Vice President and Chief Financial Officer, Johnson & Johnson, Executive Vice President and Chief Financial Officer, Johnson & Johnson. "Continued market recovery favorably impacted growth comparisons as our Pharmaceutical, Medical Device and Consumer Health businesses improved their market-leading positions across many platforms. This performance underscores the resilience of our diversified business, in addition to the agility of our colleagues to meet the needs of patients and consumers around the world. We are poised to continue our pursuit of improving human health and the well-being of people around the world while delivering long-term value to all of our stakeholders well beyond 2021."
For more details about the company's 2021 second-quarter results, and to read a message from Chairman and Chief Executive Officer Alex GorskyAlex Gorsky,Chairman and Chief Executive Officer, Johnson & Johnson, here's an infographic that highlights key stats.
Attachments
Original document
Permalink
Disclaimer
Johnson & Johnson published this content on 21 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 July 2021 12:39:09 UTC.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).